Lynparza

Major Expected Events from AstraZeneca’s R&D in H2 2018
Major Expected Events from AstraZeneca’s R&D in H2 2018
Market Realist
AstraZeneca
China
Lynparza
Tagrisso
Imfinzi
Flag link:
PARP inhibitors show promise for treating ALS and other brain disorders
PARP inhibitors show promise for treating ALS and other brain disorders
Fierce Biotech
PARP inhibitors
AstraZeneca
Lynparza
Tesaro
Zejula
ALS
Flag link:
AstraZeneca wins speedy approvals for cancer drugs in Japan
AstraZeneca wins speedy approvals for cancer drugs in Japan
Yahoo/Reuters
AstraZeneca
Japan
Imfinzi
Lynparza
Flag link:
AstraZeneca, Merck eye wider cancer drug use after study success
AstraZeneca, Merck eye wider cancer drug use after study success
Yahoo/Reuters
AstraZeneca
Merck
Lynparza
ovarian cancer
Flag link:
ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer
ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer
Fierce Pharma
AstraZeneca
Lynparza
prostate cancer
Flag link:
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
CP Wire
AstraZeneca
Merck
Lynparza
metastatic breast cancer
AACR
Flag link:
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
AstraZeneca
Merck
Lynparza
HER-2 negative breast cancer
breast cancer
Flag link:
Myriad’s breast cancer diagnostic wins approval in Japan
Myriad’s breast cancer diagnostic wins approval in Japan
Drug Delivery Business News
Myriad Genetics
diagnostics
breast cancer
Japan
Bracanalysis Diagnostic System
Lynparza
Flag link:
Tesaro Wants a Stronger Grip in Ovarian Cancer
Tesaro Wants a Stronger Grip in Ovarian Cancer
Yahoo/Motley Fool
Tesaro
AstraZeneca
Clovis Oncology
ovarian cancer
Zejula
Rubraca
Lynparza
Flag link:
AstraZeneca Goes Up Against 2 Cancer Upstarts
AstraZeneca Goes Up Against 2 Cancer Upstarts
Motley Fool
AstraZeneca
Clovis Oncology
PARP inhibitors
Lynparza
ovarian cancer
breast cancer
Rubraca
Zejula
Flag link:
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
Investors Business Daily
AstraZeneca
Lynparza
Tesaro
cancer
Rubraca
Clovis Oncology
Flag link:
Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma
Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma
Endpoints
AstraZeneca
Lynparza
Merck
ovarian cancer
asthma
Japan
Fasenra
EA Pharma
elobixibat
Flag link:
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Endpoints
AstraZeneca
PARP inhibitors
FDA
Lynparza
metastatic breast cancer
Flag link:
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
China
Opdivo
Repatha
Lynparza
drug approvals
Bristol-Myers Squibb
Amgen
AstraZeneca
Eli Lilly
Gilead Sciences
Flag link:
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Endpoints
Bristol-Myers Squibb
AstraZeneca
Opdivo
Lynparza
China
Flag link:
These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
Investors Business Daily
Europe
AstraZeneca
Lynparza
ovarian cancer
Novo Nordisk
diabetes
semaglutide
Flag link:
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
Endpoints
Pfizer
AstraZeneca
talazoparib
advanced breast cancer
Lynparza
PARP inhibitors
Flag link:
3 Companies Competing to Gain Lead in Ovarian Cancer Market
3 Companies Competing to Gain Lead in Ovarian Cancer Market
Yahoo/Zacks.com
ovarian cancer
AstraZeneca
Merck
Lynparza
Rubraca
Clovis Oncology
Zejula
Tesaro
Flag link:
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Fierce Pharma
AstraZeneca
Merck
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Zejula
Rubraca
Lynparza
Flag link:
[forum discussion]What's up in Oncology?
[forum discussion]What's up in Oncology?
Cafepharma Message Boards
Merck
oncology
drug reps
Lynparza
Flag link:

Pages